Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$12.08
+1.3%
$10.19
$3.51
$12.43
$1.81B1.831.64 million shs2.65 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$57.63
+1.9%
$55.11
$42.01
$70.51
$6.97B1.151.75 million shs1.62 million shs
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$4.49
+1.1%
$3.83
$1.92
$11.60
$234.27M2.28345,785 shs540,193 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$38.47
-1.7%
$33.38
$27.12
$60.90
$2.34B2.41967,026 shs886,981 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.93
$5.17
$4.32
$14.45
$819.75M1.221.36 million shs2.06 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
+1.26%+0.87%+15.49%+52.14%+245.14%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+1.86%+6.62%+7.18%-4.30%+8.82%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+1.13%+13.38%+6.40%+105.96%+78.17%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.66%+0.94%+11.67%-0.98%-24.55%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
0.00%+8.01%+9.41%+7.23%-29.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
3.4607 of 5 stars
1.43.00.04.23.02.50.6
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.6215 of 5 stars
2.11.00.04.42.72.54.4
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
4.4358 of 5 stars
3.04.00.04.63.03.30.0
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.9974 of 5 stars
3.42.00.04.42.60.80.6
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
3.2364 of 5 stars
3.42.00.00.02.13.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.86
Moderate Buy$10.57-12.49% Downside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.17
Hold$62.508.45% Upside
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.00
Hold$9.00100.45% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4031.01% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.86
Moderate Buy$32.86454.08% Upside

Current Analyst Ratings Breakdown

Latest HALO, KOD, TWST, VIR, and ADPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$55.00
6/18/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
5/29/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00
5/22/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/14/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.00
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform$47.00
5/12/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $14.00
5/7/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/7/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $65.00
5/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$178.96M10.25N/AN/A$1.37 per share8.82
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.02B6.99$4.74 per share12.16$2.86 per share20.15
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.86 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M7.37N/AN/A$8.07 per share4.77
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$74.21M11.05N/AN/A$8.35 per share0.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%7/30/2025 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$444.09M$3.7615.339.270.3844.76%136.91%26.05%8/5/2025 (Estimated)
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%7/30/2025 (Estimated)

Latest HALO, KOD, TWST, VIR, and ADPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.24N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.22N/AN/AN/A$282.66 millionN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/14/2025Q1 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.89-$1.09-$0.20-$1.09N/AN/A
5/7/2025Q1 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million
5/6/2025Q1 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.98$1.11+$0.13$0.93$231.21 million$264.86 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
5/1/2025Q1 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
2.92
2.82
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
3.13
8.39
7.30
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
4.62
4.62
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.79
6.79

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790151.92 million142.19 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390123.22 million120.26 millionOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9052.76 million28.55 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.24 million116.12 millionOptionable

Recent News About These Companies

Q1 2025 Vir Biotechnology Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$12.08 +0.15 (+1.26%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$12.05 -0.03 (-0.26%)
As of 07:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$57.63 +1.05 (+1.86%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$57.83 +0.20 (+0.35%)
As of 07:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$4.49 +0.05 (+1.13%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$4.45 -0.04 (-0.89%)
As of 07:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$38.47 -0.65 (-1.66%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$37.85 -0.62 (-1.61%)
As of 07:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.93 0.00 (0.00%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$6.06 +0.14 (+2.28%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.